Copenhagen, Denmark, 21 November 2024 – Today is the first day for the exercise of Curasight A/S’ (“Curasight” or “the Company”
Business Highlights during and after the third quarter of 2024 Curasight designates brain cancer as initial indication for uTREAT Clinical Phase